Literature DB >> 8582130

The effect of the timing and the administration of acarbose on postprandial hyperglycaemia.

C Rosak1, G Nitzsche, P König, U Hofmann.   

Abstract

To clarify the optimum timing for ingestion of acarbose, a 100 mg dose of this oral hypoglycaemic agent was administered 30 min before, at the beginning, and 15 min after ingestion of a test meal, and the effects of the drug on blood glucose rises were compared with increases observed after a control meal (no drug). Twenty-four patients with Type 2 diabetes were included in a randomized, open, cross-over study. The smallest increases in blood glucose (p < 0.001) occurred when acarbose was taken at the beginning and 15 min after starting the test meal (3.3 +/- 1.6 mmol l-1 and 3.3 +/- 1.4 mmol l-1). The increase in blood glucose levels when acarbose was taken 30 min before the test meal was significantly higher (4.2 +/- 1.8 mmol l-1) and it was at its maximum following the control meal (5.2 +/- 1.7 mmol l-1). Similar results were observed when the effects of acarbose on insulin and C-peptide levels were measured. It is recommended that patients should be instructed to take acarbose with their first mouthful of food.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582130     DOI: 10.1111/j.1464-5491.1995.tb00409.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  3 in total

1.  Effect of Apple Consumption on Postprandial Blood Glucose Levels in Normal Glucose Tolerance People versus Those with Impaired Glucose Tolerance.

Authors:  Yutaka Inoue; Lianne Cormanes; Kana Yoshimura; Aiko Sano; Yumiko Hori; Ryuichiro Suzuki; Ikuo Kanamoto
Journal:  Foods       Date:  2022-06-19

2.  Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.

Authors:  Christoph Rosak; Gabriele Mertes
Journal:  Diabetes Metab Syndr Obes       Date:  2012-10-12       Impact factor: 3.168

Review 3.  Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.

Authors:  Markolf Hanefeld
Journal:  Cardiovasc Diabetol       Date:  2007-08-15       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.